SCHEMBL10326564

SCHEMBL10326564

Cc1ccc(C(c2ccc(C)cc2)(c2ccc(C)cc2)C2CCCN2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C19 P33261 2/20 0.45
RAB9A P51151 2/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
TSHR P16473 1/20 0.35
CHRM2 P08172 3/20 0.35
CHRM4 P08173 2/20 0.35
CHRM5 P08912 2/20 0.35
CHRM1 P11229 2/20 0.35
CHRM3 P20309 2/20 0.35
MAPT P10636 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10326879 1.00 CYP1A2 (0.45) CYP1A2CYP2D6CYP2C19RAB9AKDM4E
SCHEMBL10326553 1.00 CYP1A2 (0.45) CYP1A2CYP2D6CYP2C19RAB9AKDM4E
SCHEMBL10326595 0.84 CYP1A2 (0.44) CYP1A2CYP2D6CYP2C19RAB9AKDM4E
SCHEMBL12295292 0.84 CYP1A2 (0.44) CYP1A2CYP2D6CYP2C19RAB9AKDM4E
SCHEMBL8354404 0.84 CYP1A2 (0.44) CYP1A2CYP2D6CYP2C19RAB9AKDM4E
SCHEMBL10326467 0.84 CYP1A2 (0.44) CYP1A2CYP2D6CYP2C19RAB9AKDM4E
SCHEMBL12295527 0.82 CYP1A2 (0.42) CYP1A2CYP2D6CYP2C19RAB9AKDM4E
SCHEMBL10326855 0.82 CYP1A2 (0.42) CYP1A2CYP2D6CYP2C19RAB9AKDM4E
SCHEMBL10326921 0.82 CYP2D6 (0.68) CYP1A2CYP2D6CYP2C19RAB9AKDM4E
SCHEMBL10326539 0.82 CYP1A2 (0.42) CYP1A2CYP2D6CYP2C19RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438989-B1 USE OF ASYMMETRIC HYDROGENATION CATALYST TAKASAGO PERFUMERY CO LTD (JP) 2016-04-13 EP disclosed
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US disclosed
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION H1-0, H1-5, ADH5 CYP1A2 1183/4885CYP2D6 1125/4885CYP2C19 2363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.